SCHEMBL20090150

SCHEMBL20090150

O=P(c1ccccc1)(c1ccccc1)c1ccc2c(ccc3cc(-c4ccc5c(ccc6c7ccccc7c7nc8ccccc8n7c56)c4)ccc32)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.41
HPGD P15428 6/20 0.41
ALDH1A1 P00352 6/20 0.41
KMT2A Q03164 7/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
MAPT P10636 6/20 0.40
POLB P06746 3/20 0.40
HSD17B10 Q99714 2/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
MEN1 O00255 5/20 0.38
CAMKK1 Q8N5S9 2/20 0.36
CAMKK2 Q96RR4 2/20 0.36
CYP1A2 P05177 2/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CASP1 P29466 1/20 0.36
CYP2C19 P33261 1/20 0.36
CASP7 P55210 1/20 0.36
BCL2 P10415 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20090147 0.98 KDM4E (0.41) KDM4EHPGDALDH1A1KMT2ASMN1; SMN2
SCHEMBL19960079 0.94 KDM4E (0.44) KDM4EHPGDALDH1A1KMT2ASMN1; SMN2
SCHEMBL19960148 0.91 KDM4E (0.40) KDM4EHPGDALDH1A1KMT2ASMN1; SMN2
SCHEMBL20090146 0.90 KDM4E (0.44) KDM4EHPGDALDH1A1KMT2ASMN1; SMN2
SCHEMBL19960146 0.89 ALDH1A1 (0.46) KDM4EHPGDALDH1A1KMT2ASMN1; SMN2
SCHEMBL20090097 0.89 HPGD (0.38) KDM4EHPGDALDH1A1KMT2ASMN1; SMN2
SCHEMBL20090237 0.88 HPGD (0.35) KDM4EHPGDALDH1A1KMT2ASMN1; SMN2
SCHEMBL15479213 0.88 KDM4E (0.45) KDM4EHPGDALDH1A1KMT2ASMN1; SMN2
SCHEMBL15479210 0.88 KDM4E (0.45) KDM4EHPGDALDH1A1KMT2ASMN1; SMN2
SCHEMBL19960084 0.88 KDM4E (0.42) KDM4EHPGDALDH1A1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10355225-B2 Heterocyclic compound and organic light emitting element comprising same LG CHEM, LTD. (KR) 2019-07-16 US disclosed
US-20180114923-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME LG CHEM, LTD. (KR) 2018-04-26 US disclosed
US-20180114923-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME LG CHEM, LTD. (KR) 2018-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180114923-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME CRY1, CRY2, PER2 KDM4E 1997/4885HPGD 2982/4885ALDH1A1 750/4885
US-10355225-B2 Heterocyclic compound and organic light emitting element comprising same CRY1, CRY2, PER2 KDM4E 1997/4885HPGD 2982/4885ALDH1A1 750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.